Mar 04, 2024 8:01am EST Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
Feb 15, 2024 8:01am EST Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Jan 17, 2024 7:30am EST Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
Nov 30, 2023 8:00am EST FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Nov 08, 2023 4:01pm EST Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
Nov 01, 2023 8:00am EDT Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
Oct 10, 2023 8:00am EDT Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
Oct 03, 2023 8:00am EDT Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Sep 25, 2023 8:30am EDT Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Sep 18, 2023 9:00am EDT Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
